ALIMERA SCIENCES INC: Nasdaq/NYSE listing notice — Alimera raises $12M via Series B preferred, eliminates Series A preference, receives Nasdaq deficiency notice

March 23, 2023, the Company received a notice (the “MVPHS Notice”) from Nasdaq, stating that the Company’s listed securities failed to comply with the $15 million market value of publicly held shares (“Market Value of Publicly Held Shares”) requirement for continued listing on the Nasdaq Global Market in accordance with Nasdaq Listing Rule 5450(b)(2)(C) based on the Company’s Market Value of Publicly Held Shares for the 30 consecutive business days prior to the date of the MVPHS Notice. The MVPHS Notice is only a notification of deficiency, not of imminent delisting, and has no immediate effec

On March 24, 2023, the Company filed a Certificate of Elimination with the Secretary of State of the State of Delaware for the Series C Preferred Stock.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year In connection with the Transactions and the Repurchase, on March 24, 2023, the Company filed the Certificate of Designation authorizing the Series B Preferred Stock and the Series A Elimination Certificate eliminating the Series A Preferred Stock, each with the Secretary of State of the State of Delaware.

On March 24, 2023, Alimera Sciences, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with (i) Velan Capital Master Fund LP (“Velan”) and (ii) a fund and accounts managed by Caligan Partners LP (“Caligan” and collectively with Velan, the “Investors”) for the sale of up to 27,000 shares of the Company’s newly designated Series B Convertible Preferred Stock, par value $0.01 per share (the “Series B Preferred”) and warrants (the “Warrants”) to purchase up to 5,714,286 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), for an aggregate purchase price of up to $27.0 million in two tranches